{
  "docId": "019de073-8606-762c-9e2e-06d280bc8199",
  "docSlug": "fe3546a131d6b03dbc05b580d2cda1c4",
  "documentTitle": "CTI BioPharma | Investor Presentation Deck | 24 slides",
  "authorId": "cti-biopharma",
  "authorName": "CTI BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 24,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "appendix_disclosure",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "Includes clinical trial data from PERSIST-2 study.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8606-762c-9e2e-06d280bc8199/8",
  "deckHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199",
  "deckJsonHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199.json",
  "deckAnchorHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.12,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "VONJO is granted accelerated approval for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis with a baseline platelet count of <50 × 10⁹/L. U.S. Prescribing Information for VONJO (pacritinib) February 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f411f43c-b401-4d15-8a6a-5d6aa20bf54a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.61,
        "y": 0.35
      },
      "kind": "list",
      "text": "Warnings and Precautions: Hemorrhage, Diarrhea, Thrombocytopenia, Prolonged QT interval, Risk of infection, Another JAK-inhibitor risk note",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d49d447d-5a07-4006-9f71-52bb7e96cbdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.12,
        "y": 0.35
      },
      "kind": "table",
      "text": "Most Common Adverse Reactions table comparing VONJO and Best Available Therapy",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d059147-edd8-449a-8434-d77d784c7ee3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.06,
        "y": 0.17
      },
      "kind": "title",
      "text": "VONJO has a predictable and manageable safety profile in PERSIST-2 (platelet counts ≤100 × 10⁹/L)",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92eee132-b7d2-4a84-9e6f-8e8ce6f4feb7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "VONJO: Proven Safety in Cytopenic Myelofibrosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1557408-2d0b-4385-b8dd-47c7358675eb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}